The Future of
ECG Starts
with Us.

The Future of ECG
Starts with Us.

Simplifying Cardiac Analysis

Cardiac Insight, Inc. a privately held medical device company based in Bellevue, WA., is renowned for its cardiac diagnostic products, Cardea SOLO and Cardea 20/20.

It has been providing cardiac evaluations since its first product in 2013. Pioneered by Dr. Dave Hadley and Dr. Vic Frolicher, the Cardea 20/20, a handheld 12-lead ECG device that enhances electrocardiogram reliability for detecting cardiovascular issues in young athletes, is transforming athletic heart care. 

In 2017 they introduced the Cardea SOLO, a comfortable, 7-day wearable, ambulatory sensor with software-assisted ECG analysis. 

In 2021, Cardiac Insight joined forces with global electronic components leader DreamTech, solidifying their position as a leading innovator in cardiac healthcare diagnostics, poised for exponential growth.

The Cardiac Insight Difference

Commitment to Excellence

At the heart of Cardiac Insight is a commitment to advancing the development of sensors and algorithms that prioritize accuracy in analyzing high-quality ECG data—a pivotal element in our mission to save lives.


From acquiring a device to reimbursement, we've designed a streamlined process that makes the journey easier for our partners.

Focus ‏‏‎

The unique needs of our clients remain central to our ethos. Our promise: efficiency, cost-effectiveness, simplicity, and unparalleled support.

Evolving Advancements

Through our unwavering commitment to learning and innovation, we remain dedicated to making ECG analysis more accessible for healthcare providers and patients.

Dr. Hadley's Journey of Innovation

From seismic wave analysis to reshaping cardiac screening, Dr. Hadley’s story is nothing short of exceptional. After earning a Ph.D. at Caltech—and then co-founding Sierra Geophysics—his trajectory took a turn to software before joining forces with Quinton Cardiology.

In collaboration with Dr. Victor Froelicher, Dr. Hadley brought momentum to modern ECG analysis by shaping the “Stanford Criteria” and the life-saving Cardea 20/20. Today, his spirit of innovation thrives as he continues to redefine the boundaries of cardiac care.

Unveiling Cardea SOLO

Meet Cardea SOLO: an ambulatory ECG system that simplifies the monitoring process. With the ease of recording their ECG from the comfort of their home, and with fast, in-office software analytics, Cardea SOLO generates reports in under five minutes

Explore the Cardea SOLO System


A feather-light, water-resistant, and wire-free device that continuously records over seven days.


Equipped for USB connectivity to a Windows PC, this cable transfers the ECG data directly to the PC and Cardea SOLO software for analysis


Our software not only generates draft summary reports on-the-fly, but also empowers clinicians with key clinical tools—from trace and R.R. view to beat morphologies and calipers.

Competitor Chart

Cardea SOLO

Cardiac insight

Zio®XT & Zio®AT




CAM™ Patch


BodyGuardian™ MINI

Boston Scientific

Provides interpretive findings

Yes, provided by the software

Yes, provided by software by a diagnostic service provider facilitated by proprietary software

Full narrative summaries 12 are provided by a diagnostic service provider

Findings summary 10 provided by a diagnostic service provider or by your trained clinical staff

No interpretive statements. 8 Computer-generated analysis provided by diagnostic service provider.

Provides full disclosure

Yes, two clicks to see any heartbeat

Only available by request 1 to a diagnostic service provider

Limited to event data 4

from a diagnostic service provider

Yes 6 from a diagnostic service provider

Limited to arrhythmia events 8 from a diagnostic service provider

Who owns the data?

You do, the prescribing physician. 

The diagnostic service provider1

The diagnostic service provider4

Can be the diagnostic service provider or the prescribing physician6

The diagnostic service provider

Clinical analysis of data

So fast it can be done in-office at time of patient visit

Requires diagnostic service provider 1

Requires diagnostic service provider4

Option to use diagnostic service provider or your trained clinical staff 6

Requires diagnostic service provider 14

Who can wear it?


18 years or older 2


18-21 years and adults 5

Includes pediatric indication (not weighing less than 10 kg) 7

Includes pediatric indication (not weighing less than 10 kg) 8

Report turnaround time

Can be done in-office during patient visit

4 days maximum but usually 24-hours1

(depending on SLA* agreement and location in queue)

Posted in less than 48 hours 11

(depending on SLA* agreement and location in queue)

Option to use diagnostic service with 2-day turnaround time

(depending on SLA* agreement and location in queue) or your trained clinical staff 6

Depends on SLA* agreement and location in queue of diagnostic service provider.

*Service level agreement

1 Zio XT for detecting cardiac arrhythmias (

2 K190593.pdf (

3 Zio Monitoring (

4 ePatch_Overall-Brochure_220-0730-01-Rev-A-1.11.21.pdf (

5 ATTACHMENT I (, K171410

6 Carnation Ambulatory Monitor Product Brochure (

7 Ambulatory ECG Monitor Coding & Reimbursement (

8 Faros Mobile (, K182030

9 BodyGuardian MINI Remote Cardiac Monitor – For Physicians (

10 Enhanced-CAM-Report-Overview-050521-DN000344B.pdf (

11 Holter-Report-Sales-Aid-220-0848-01-Rev.-B-2.7.22-Final.pdf (

12 ePatch – BioTelemetry, a Philips company (

13  Zio Monitoring (

14  Healthcare Professional Support – For Physicians (

15  eCopy K162503-S001.pdf (

16  ATTACHMENT I (, K171410

17  K210036.pdf (

All online references retrieved 28 July2023

All trademarks are the property of their respective owners.

*Reference: Turakhia, M.P., Hoang, D.D., Zimetbaum, P., Miller, J.D., Froelicher, V.F., Kumar, U.N., Xu, X.Y., Yang, F., Heidenreich, P.A. (2013). Diagnostic utility of a novel leadless arrhythmia monitoring device. American Journal of Cardiology 112(4), 520-524. **Longer if outsourced

Comparative product Information is for convenience and general information purposes only. It is obtained from publicly available, third-party sources and is subject to error, omission, or change without notice. Cardiac Insight makes no representation of its suitability for any purpose. Refer to individual manufacturer documentation for more information.

Cardea 20/20

With the industry’s lowest false-positive rate of ~2%, the Cardea 20/20 ECG stands as a leader in automated 12-lead ECG systems. Its life-saving purpose? To prevent sudden cardiac issues by identifying cardiac conditions in active youth and athletes using the International Consensus Criteria1.

Explore the Cardea 20/20 System

Minimize False Positives

Our device registers strikingly fewer false positives compared to the 30% rate seen in some other devices.

Precision Interpretation

Advanced algorithms that adhere to ANSI/AAMI standards ensure the 20/20’s software can interpret ECG data with precision.

Flexible Testing
‏‏‎ ‎

Our lightweight ECG transmitter is designed for easy connectivity to a standard Windows PC and can be effortlessly transitioned across locations.

Let's Talk.

1 Sharma S, Drezner J, Baggish A, et al. International Recommendations for Electrocardiographic Interpretation in Athletes. J Am Coll Cardiol. 2017 Feb, 69 (8) 1057–1075.

Innovation Meets Simplicity